230 related articles for article (PubMed ID: 20420689)
21. Dysregulation of Neuronal Calcium Signaling via Store-Operated Channels in Huntington's Disease.
Czeredys M
Front Cell Dev Biol; 2020; 8():611735. PubMed ID: 33425919
[TBL] [Abstract][Full Text] [Related]
22. YAC128 Huntington's disease transgenic mice show enhanced short-term hippocampal synaptic plasticity early in the course of the disease.
Ghilan M; Bostrom CA; Hryciw BN; Simpson JM; Christie BR; Gil-Mohapel J
Brain Res; 2014 Sep; 1581():117-28. PubMed ID: 24949563
[TBL] [Abstract][Full Text] [Related]
23. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.
Bezprozvanny I
Subcell Biochem; 2007; 45():323-35. PubMed ID: 18193642
[TBL] [Abstract][Full Text] [Related]
24. Deranged neuronal calcium signaling and Huntington disease.
Bezprozvanny I; Hayden MR
Biochem Biophys Res Commun; 2004 Oct; 322(4):1310-7. PubMed ID: 15336977
[TBL] [Abstract][Full Text] [Related]
25. Cell-Specific Deletion of PGC-1α from Medium Spiny Neurons Causes Transcriptional Alterations and Age-Related Motor Impairment.
McMeekin LJ; Li Y; Fox SN; Rowe GC; Crossman DK; Day JJ; Li Y; Detloff PJ; Cowell RM
J Neurosci; 2018 Mar; 38(13):3273-3286. PubMed ID: 29491012
[TBL] [Abstract][Full Text] [Related]
26. Tetrabenazine treatment for Huntington's disease-associated chorea.
Ondo WG; Tintner R; Thomas M; Jankovic J
Clin Neuropharmacol; 2002; 25(6):300-2. PubMed ID: 12469001
[TBL] [Abstract][Full Text] [Related]
27. Tetrahydrocarbazoles decrease elevated SOCE in medium spiny neurons from transgenic YAC128 mice, a model of Huntington's disease.
Czeredys M; Maciag F; Methner A; Kuznicki J
Biochem Biophys Res Commun; 2017 Feb; 483(4):1194-1205. PubMed ID: 27553284
[TBL] [Abstract][Full Text] [Related]
28. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
29. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
[TBL] [Abstract][Full Text] [Related]
30. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.
Fan MM; Fernandes HB; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2007 Apr; 27(14):3768-79. PubMed ID: 17409241
[TBL] [Abstract][Full Text] [Related]
31. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
[TBL] [Abstract][Full Text] [Related]
32. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.
Milnerwood AJ; Raymond LA
J Physiol; 2007 Dec; 585(Pt 3):817-31. PubMed ID: 17947312
[TBL] [Abstract][Full Text] [Related]
33. Foundation-directed therapeutic development in Huntington's disease.
Dominguez C; Munoz-Sanjuan I
J Med Chem; 2014 Jul; 57(13):5479-88. PubMed ID: 24432836
[TBL] [Abstract][Full Text] [Related]
34. Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease.
de Paula Nascimento-Castro C; Wink AC; da Fônseca VS; Bianco CD; Winkelmann-Duarte EC; Farina M; Rodrigues ALS; Gil-Mohapel J; de Bem AF; Brocardo PS
Neural Plast; 2018; 2018():4056383. PubMed ID: 30186318
[TBL] [Abstract][Full Text] [Related]
35. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
36. Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease.
Covey DP; Dantrassy HM; Zlebnik NE; Gildish I; Cheer JF
J Neurosci; 2016 May; 36(18):4993-5002. PubMed ID: 27147652
[TBL] [Abstract][Full Text] [Related]
37. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
38. Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model.
Kim D; Jeon J; Cheong E; Kim DJ; Ryu H; Seo H; Kim YK
Mol Neurobiol; 2016 May; 53(4):2276-86. PubMed ID: 25976370
[TBL] [Abstract][Full Text] [Related]
39. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.
Tang TS; Slow E; Lupu V; Stavrovskaya IG; Sugimori M; Llinás R; Kristal BS; Hayden MR; Bezprozvanny I
Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2602-7. PubMed ID: 15695335
[TBL] [Abstract][Full Text] [Related]
40. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
